Vivendi (VIV-FR)


Vivendi stock research in summary

vivendi.com


Latest Obermatt Ranks

Country France
Industry Integrated Telecommunication
Index EURO STOXX 50, CAC 40, CAC All, SBF 120
Size class XX-Large

November 10, 2017. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock






 

Research History: Vivendi

STOCK RESEARCH SUMMARY 2014 2015 2016 2017
STOCK VALUE RANKS
91
43
90
26
STOCK GROWTH RANKS
38
56
27
67
STOCK SAFETY RANKS
52
71
32
19
COMBINED STOCK RANKS
70
73
45
20

Last update of Combined Rank: 10-Nov-2017

Historic Vivendi stock analysis based on the Obermatt Method. The higher the rank, the better is Vivendi in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2014 2015 2016 2017
PRICE VS. REVENUES (P/S)
43
43
49
32
PRICE VS. PROFITS (P/E)
100
1
73
26
PRICE VS. CAPITAL (Market-to-Book)
81
76
76
46
DIVIDEND YIELD
76
93
100
46
CONSOLIDATED RANK: VALUE
91
43
90
26

Last update of Value Rank: 10-Nov-2017

Vivendi stock analysis in respect to important value ratios. The higher the rank, the lower the value ratio; except for dividend yield where the rank is higher the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2014 2015 2016 2017
REVENUE GROWTH
16
65
38
64
PROFIT GROWTH
34
37
40
42
STOCK RETURNS
53
51
33
73
CONSOLIDATED RANK: GROWTH
38
56
27
67

Financial reporting date of Growth Rank: 30-Jun-2017

Vivendi stock analysis in respect to important growth metrics. The higher the rank, the higher the growth and returns.


Safety Metrics in Detail

SAFETY METRICS 2014 2015 2016 2017
LEVERAGE
84
88
69
81
REFINANCING
19
LIQUIDITY
19
23
8
3
CONSOLIDATED RANK: SAFETY
52
71
32
19

Financial reporting date of Safety Rank: 3-Nov-2017

Vivendi stock analysis in respect ot important safety metrics. The higher the rank, the lower the leverage and the more cash is available to service the debt.

Stock analysis by the purely finance fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Vivendi (VIV-FR) from November 10, 2017.